The FDA has approved the use of sublingual sufentanil (Dsuvia) to treat acute pain in adults in a medically supervised setting…
A Balancing Act: Tips to Ensure Optimal Screening & Treatment for Osteoporosis
Patients with rheumatic diseases may be undertreated for osteoporosis. To decrease fracture risk for at-risk patients, rheumatologists can engage patients in shared decision making with regular screening and education about treatment options…
Ustekinumab May Be Effective for Lupus
New research underscores the possibility that interleukin (IL) 12, IL-23 or both play roles in the immunopathology of SLE. In the study, when added to standard-of-care treatment for active SLE, ustekinumab demonstrated better efficacy than placebo and had a safety profile consistent with that of ustekinumab therapy in other diseases…
Final 2019 Physician Reimbursement Rule Released by CMS Includes Victories for Rheumatology
On Nov. 1, after months of advocacy efforts spearheaded by the ACR and others, the Centers for Medicare and Medicaid Services (CMS) released the CY 2019 Medicare physician fee schedule rule, and it included several victories for rheumatology. Upon initial review, it appears the CMS has taken into account the concerns expressed by the ACR and…
5-Year Data on Secukinumab in AS; Oliceridine Not Recommended for FDA Approval
In a long-term study, secukinumab proved safe and effective for treating ankylosing spondylitis…
Ixekizumab Improves Outcomes of Ankylosing Spondylitis
NEW YORK (Reuters Health)—Ixekizumab improves signs and symptoms in patients with radiographic axial spondyloarthritis (ankylosing spondylitis), according to results from the COAST-W study. “Ankylosing spondylitis is a chronic and debilitating disease, and I have a large number of patients who have failed TNF inhibitors,” says Dr. Atul Deodhar from Oregon Health and Science University, Portland….
Is More Better? Weight Loss Analysis in Older Patients with Knee OA
Obesity is a modifiable risk factor for many patients with knee osteoarthritis (OA), and the National Institutes of Health recommend an initial weight loss goal of 10%. But how does losing more weight affect knee OA patients? In a new study, researchers compared the outcomes of knee OA patients who lost more and less than the recommended 10% of their baseline weight, finding significant improvement in health-related quality of life and reduction in pain for patients who lost twice what’s recommended…
2018 MIPS Reporting via RISE: Are You Ready?
It’s time to prepare for 2018 MIPS reporting via the Rheumatology Informatics System for Effectiveness (RISE) registry, and the ACR is here to help. To ensure you’re ready to submit your data to the CMS, RISE users should take the following steps: Complete the survey to notify the ACR of your intent to report via…
Protect Your Practice: Action Update From the ACR’s Insurance Subcommittee
Both private and academic rheumatology practices face payer challenges that put the health of their patients and their practices at risk. To make sure the rheumatologist perspective is heard by payers, “the ACR’s Insurance Subcommittee (ISC) serves as the interface between payers and our members and ACR colleagues,” explains Sean Fahey, MD, a rheumatologist in…
RheumPAC Champions Recognized
Election Day 2018 has come and gone, and a new class of legislators will be joining the ranks of Congress in January. RheumPAC is the most important tool we have to establish relationships with our new legislators and this year, our ACR volunteer leaders stepped up and matched all donations to RheumPAC leading up to…
- « Previous Page
- 1
- …
- 302
- 303
- 304
- 305
- 306
- …
- 815
- Next Page »